(Q34651968)

3 August 2017

Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity (English)

1 reference

3 August 2017

1 reference

angiogenesis inhibitor

1 reference

Danfang Zhang

1

1 reference

3 August 2017

Eva-Maria E Hedlund

2

1 reference

3 August 2017

Sharon Lim

3

1 reference

3 August 2017

Fang Chen

4

1 reference

3 August 2017

Yin Zhang

5

1 reference

3 August 2017

Baocun Sun

6

1 reference

3 August 2017

Yihai Cao

7

1 reference

3 August 2017

language of work or name

English

0 references

publication date

18 February 2011

1 reference

3 August 2017

6

1 reference

Proceedings of the National Academy of Sciences of the United States of America

inferred from page(s)

published in

1 reference

3 August 2017

108

1 reference

3 August 2017

10

1 reference

3 August 2017

4117-4122

1 reference

VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy

3 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Tumor-derived VEGF modulates hematopoiesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Antiangiogenic therapies in breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Mechanisms of adverse effects of anti-VEGF therapy for cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Cachexia in cancer patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Carboplatin versus cisplatin in solid tumors: an analysis of the literature

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Characterization of a cancer cachectic factor

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Dose-Dependent Metabolism, Therapeutic Effect, and Toxicity of Anticancer Drugs in Man

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3053963

Off-tumor target--beneficial site for antiangiogenic cancer therapy?

7 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.1016220108

Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.1016220108

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.1016220108

21 January 2018

Drug markers questioned

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21367692

12 December 2020

inferred from PubMed ID database lookup

Population pharmacokinetc/pharmacodynamic modeling of paclitaxel and carboplatin in ovarian cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21367692

12 December 2020

inferred from PubMed ID database lookup

Optimizing the delivery of cancer drugs that block angiogenesis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21367692

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1073/PNAS.1016220108

1 reference

3 August 2017

0 references

1 reference

3 August 2017

1 reference